Sionna Therapeutics (NASDAQ:SION) Downgraded to “Market Perform” Rating by Citizens Jmp

Sionna Therapeutics (NASDAQ:SION) was downgraded by research analysts at Citizens Jmp from an “outperform” rating to a “market perform” rating in a research report issued on Monday.

A number of other equities research analysts have also issued reports on SION. Stifel Nicolaus reissued a “hold” rating and issued a $7.00 price objective on shares of Sionna Therapeutics in a report on Monday. Raymond James Financial downgraded shares of Sionna Therapeutics from a “strong-buy” rating to a “market perform” rating in a report on Monday. JonesTrading lifted their price target on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Royal Bank Of Canada upgraded Sionna Therapeutics from an “underperform” rating to a “sector perform” rating and set a $5.00 price objective on the stock in a report on Monday. Finally, BTIG Research reiterated a “buy” rating and issued a $58.00 price objective on shares of Sionna Therapeutics in a research report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $42.22.

Sionna Therapeutics Price Performance

Sionna Therapeutics stock traded down $46.98 during trading on Monday, reaching $4.05. 23,315,454 shares of the company were exchanged, compared to its average volume of 548,288. The stock’s 50 day simple moving average is $42.35 and its two-hundred day simple moving average is $40.42. The company has a market capitalization of $183.33 million, a P/E ratio of -1.88 and a beta of 1.32. Sionna Therapeutics has a 52-week low of $4.01 and a 52-week high of $54.97.

Sionna Therapeutics (NASDAQ:SION) last issued its earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.02). As a group, equities analysts forecast that Sionna Therapeutics will post -2.63 earnings per share for the current year.

Insider Activity

In other news, Director Peter A. Thompson sold 115,844 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the sale, the director owned 2,555,877 shares of the company’s stock, valued at approximately $116,292,403.50. This represents a 4.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 115,844 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the completion of the transaction, the director directly owned 2,555,877 shares of the company’s stock, valued at approximately $116,292,403.50. The trade was a 4.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 403,726 shares of company stock worth $18,259,354. 5.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sionna Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Viking Global Investors LP increased its position in shares of Sionna Therapeutics by 8.2% during the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after acquiring an additional 242,427 shares during the period. BlackRock Inc. purchased a new position in Sionna Therapeutics in the second quarter valued at $64,875,000. Jennison Associates LLC grew its stake in Sionna Therapeutics by 30.1% during the 1st quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock worth $58,179,000 after purchasing an additional 335,942 shares in the last quarter. Vanguard Group Inc. increased its holdings in Sionna Therapeutics by 3.7% during the 4th quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock worth $48,749,000 after purchasing an additional 41,797 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its position in Sionna Therapeutics by 30.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 831,373 shares of the company’s stock valued at $34,203,000 after purchasing an additional 193,613 shares in the last quarter.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.